Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29485754 | 1.00 | MLYCD (1.00) | MLYCD | |
| SCHEMBL648037 | 0.81 | MLYCD (0.69) | MLYCD | |
| SCHEMBL649533 | 0.80 | MLYCD (0.67) | MLYCD | |
| SCHEMBL647659 | 0.80 | MLYCD (1.00) | MLYCD | |
| SCHEMBL647139 | 0.79 | MLYCD (1.00) | MLYCD | |
| SCHEMBL6730506 | 0.79 | MLYCD (0.65) | MLYCD | |
| SCHEMBL1895701 | 0.76 | MLYCD (0.64) | MLYCD | |
| SCHEMBL6538428 | 0.75 | MLYCD (0.62) | MLYCD | |
| SCHEMBL1903557 | 0.75 | MLYCD (0.64) | MLYCD | |
| SCHEMBL648813 | 0.72 | MLYCD (0.62) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | IMBRIA PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250340523-A1 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250262310-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250235447-A1 | METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND METHODS OF INCREASING THE EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12318382-B2 | Methods of treating rheumatic diseases using trimetazidine-based compounds | IMBRIA PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12318453-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | IMBRIA PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4531845-A1 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-118647381-A | Methods of treating cardiovascular conditions and methods of increasing cardiac metabolic efficiency | 安布里亚制药公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4426301-A1 | METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND METHODS OF INCREASING THE EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4092013-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220288215-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220249463-A1 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | IMBRIA PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220241272-A1 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | IMBRIA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226313-A1 | COMBINATION THERAPIES THAT INCLUDE AN AGENT THAT PROMOTES GLUCOSE OXIDATION AND AN INHIBITOR OF PYRUVATE DEHYDROGENASE KINASE | IMBRIA PHARMACEUTICALS, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11376330-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | IMBRIA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3641769-B1 | 1-[(2,3,4-TRIMETHOXYPHENYL)METHYL]-PIPERAZINE DERIVATIVE, COMPOSITIONS THEREOF AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220168431-A1 | METHODS OF TREATING CANCER USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3976103-A1 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Imbria Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976101-A1 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Imbria Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318382-B2 | Methods of treating rheumatic diseases using trimetazidine-based compounds | TRIM4, HMGCR, FAH | MLYCD 2578/4885 |
| US-20250262310-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20220249463-A1 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | CPT1B, FABP3, TNNI3 | MLYCD 148/4885 |
| US-20250235447-A1 | METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND METHODS OF INCREASING THE EFFICIENCY OF CARDIAC METABOLISM | PC, CPT1B, GOT2 | MLYCD 115/4885 |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | TNNT2, TNNC1, CPT1B | MLYCD 1083/4885 |
| US-20220226313-A1 | COMBINATION THERAPIES THAT INCLUDE AN AGENT THAT PROMOTES GLUCOSE OXIDATION AND AN INHIBITOR OF PYRUVATE DEHYDROGENASE KINASE | PDK1, PDK4, PDK2 | MLYCD 142/4885 |
| US-11376330-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20220168431-A1 | METHODS OF TREATING CANCER USING TRIMETAZIDINE-BASED COMPOUNDS | TRIM4, TRIM58, CKMT1A; CKMT1B | MLYCD 2334/4885 |
| US-12318453-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20220241272-A1 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | CPT1A, CPT1B, MMP1 | MLYCD 211/4885 |
| US-20250340523-A1 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, GOT2, CPT1B | MLYCD 58/4885 |
| US-20220288215-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | CPT1B, PFKP, PTK2 | MLYCD 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.